Login to Your Account

Repros' Androxal moving toward NDA by year-end

By Randy Osborne
Staff Writer

Friday, November 7, 2014

Repros Therapeutics Inc.'s CEO Joseph Podolski acknowledged the "nauseating" Wall Street ride for the company of late, but told investors that "with time and continued progress, our share prices are going to move in the right direction."

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription